nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—EGFR—type 2 diabetes mellitus	0.175	0.594	CbGaD
Gefitinib—CYP3A4—type 2 diabetes mellitus	0.0639	0.217	CbGaD
Gefitinib—ALB—type 2 diabetes mellitus	0.0557	0.189	CbGaD
Gefitinib—ORM1—Nateglinide—type 2 diabetes mellitus	0.0289	0.0671	CbGbCtD
Gefitinib—ALB—Gliclazide—type 2 diabetes mellitus	0.0189	0.0438	CbGbCtD
Gefitinib—ALB—Repaglinide—type 2 diabetes mellitus	0.0178	0.0412	CbGbCtD
Gefitinib—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0148	0.0344	CbGbCtD
Gefitinib—ALB—Valsartan—type 2 diabetes mellitus	0.0131	0.0304	CbGbCtD
Gefitinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.013	0.0302	CbGbCtD
Gefitinib—CYP2C19—Gliclazide—type 2 diabetes mellitus	0.0122	0.0284	CbGbCtD
Gefitinib—ALB—Nateglinide—type 2 diabetes mellitus	0.0122	0.0282	CbGbCtD
Gefitinib—CYP2C9—Glimepiride—type 2 diabetes mellitus	0.012	0.0278	CbGbCtD
Gefitinib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0119	0.0277	CbGbCtD
Gefitinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0116	0.0269	CbGbCtD
Gefitinib—CYP2C9—Glipizide—type 2 diabetes mellitus	0.011	0.0254	CbGbCtD
Gefitinib—CYP2C19—Pioglitazone—type 2 diabetes mellitus	0.0104	0.0241	CbGbCtD
Gefitinib—CYP2C19—Chlorpropamide—type 2 diabetes mellitus	0.0104	0.0241	CbGbCtD
Gefitinib—CYP2C9—Gliclazide—type 2 diabetes mellitus	0.0102	0.0236	CbGbCtD
Gefitinib—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.00979	0.0227	CbGbCtD
Gefitinib—CYP2C19—Rosiglitazone—type 2 diabetes mellitus	0.00961	0.0223	CbGbCtD
Gefitinib—CYP2C19—Tolbutamide—type 2 diabetes mellitus	0.00928	0.0215	CbGbCtD
Gefitinib—CYP2C9—Pioglitazone—type 2 diabetes mellitus	0.00866	0.0201	CbGbCtD
Gefitinib—CYP2C9—Chlorpropamide—type 2 diabetes mellitus	0.00866	0.0201	CbGbCtD
Gefitinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0084	0.0195	CbGbCtD
Gefitinib—ALB—Glyburide—type 2 diabetes mellitus	0.00822	0.0191	CbGbCtD
Gefitinib—CYP2C9—Rosiglitazone—type 2 diabetes mellitus	0.00799	0.0185	CbGbCtD
Gefitinib—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.00792	0.0184	CbGbCtD
Gefitinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00781	0.0181	CbGbCtD
Gefitinib—CYP2C9—Tolbutamide—type 2 diabetes mellitus	0.00772	0.0179	CbGbCtD
Gefitinib—ALB—Losartan—type 2 diabetes mellitus	0.00752	0.0174	CbGbCtD
Gefitinib—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.00731	0.0169	CbGbCtD
Gefitinib—CYP2C9—Valsartan—type 2 diabetes mellitus	0.00706	0.0164	CbGbCtD
Gefitinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00696	0.0161	CbGbCtD
Gefitinib—CYP2C9—Nateglinide—type 2 diabetes mellitus	0.00656	0.0152	CbGbCtD
Gefitinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00637	0.0148	CbGbCtD
Gefitinib—CYP2C9—Irbesartan—type 2 diabetes mellitus	0.00629	0.0146	CbGbCtD
Gefitinib—CYP3A5—Losartan—type 2 diabetes mellitus	0.00605	0.014	CbGbCtD
Gefitinib—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.006	0.0139	CbGbCtD
Gefitinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00577	0.0134	CbGbCtD
Gefitinib—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.00575	0.0133	CbGbCtD
Gefitinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00557	0.0129	CbGbCtD
Gefitinib—CYP2C19—Glyburide—type 2 diabetes mellitus	0.00533	0.0124	CbGbCtD
Gefitinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00504	0.0117	CbGbCtD
Gefitinib—CYP2C19—Losartan—type 2 diabetes mellitus	0.00488	0.0113	CbGbCtD
Gefitinib—CYP2C9—Glyburide—type 2 diabetes mellitus	0.00443	0.0103	CbGbCtD
Gefitinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.0043	0.00997	CbGbCtD
Gefitinib—CYP2C9—Losartan—type 2 diabetes mellitus	0.00405	0.0094	CbGbCtD
Gefitinib—ABCB1—Losartan—type 2 diabetes mellitus	0.00393	0.00912	CbGbCtD
Gefitinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00382	0.00885	CbGbCtD
Gefitinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00366	0.00848	CbGbCtD
Gefitinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00366	0.00848	CbGbCtD
Gefitinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00346	0.00802	CbGbCtD
Gefitinib—ERBB3—peripheral nervous system—type 2 diabetes mellitus	0.00261	0.0693	CbGeAlD
Gefitinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00258	0.00598	CbGbCtD
Gefitinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00236	0.00547	CbGbCtD
Gefitinib—SBK1—retina—type 2 diabetes mellitus	0.00158	0.042	CbGeAlD
Gefitinib—ERBB3—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.00132	1	CbGdCrCtD
Gefitinib—CHEK2—adipose tissue—type 2 diabetes mellitus	0.00103	0.0273	CbGeAlD
Gefitinib—CSNK1E—islet of Langerhans—type 2 diabetes mellitus	0.00102	0.0271	CbGeAlD
Gefitinib—IRAK4—islet of Langerhans—type 2 diabetes mellitus	0.001	0.0267	CbGeAlD
Gefitinib—MKNK2—islet of Langerhans—type 2 diabetes mellitus	0.000936	0.0249	CbGeAlD
Gefitinib—IRAK1—islet of Langerhans—type 2 diabetes mellitus	0.000936	0.0249	CbGeAlD
Gefitinib—CSNK1E—retina—type 2 diabetes mellitus	0.000872	0.0232	CbGeAlD
Gefitinib—MKNK2—retina—type 2 diabetes mellitus	0.0008	0.0213	CbGeAlD
Gefitinib—ERBB3—nephron tubule—type 2 diabetes mellitus	0.000792	0.0211	CbGeAlD
Gefitinib—MKNK1—retina—type 2 diabetes mellitus	0.00079	0.021	CbGeAlD
Gefitinib—MKNK2—nephron tubule—type 2 diabetes mellitus	0.000754	0.02	CbGeAlD
Gefitinib—IRAK1—nephron tubule—type 2 diabetes mellitus	0.000754	0.02	CbGeAlD
Gefitinib—CSNK1E—pancreas—type 2 diabetes mellitus	0.000717	0.0191	CbGeAlD
Gefitinib—CSNK1E—cortex of kidney—type 2 diabetes mellitus	0.000703	0.0187	CbGeAlD
Gefitinib—ERBB3—kidney—type 2 diabetes mellitus	0.000696	0.0185	CbGeAlD
Gefitinib—ERBB3—pancreas—type 2 diabetes mellitus	0.000692	0.0184	CbGeAlD
Gefitinib—MKNK2—cardiovascular system—type 2 diabetes mellitus	0.000677	0.018	CbGeAlD
Gefitinib—EGFR—adipose tissue—type 2 diabetes mellitus	0.000676	0.018	CbGeAlD
Gefitinib—MKNK1—cardiovascular system—type 2 diabetes mellitus	0.000668	0.0178	CbGeAlD
Gefitinib—MKNK2—pancreas—type 2 diabetes mellitus	0.000658	0.0175	CbGeAlD
Gefitinib—IRAK1—pancreas—type 2 diabetes mellitus	0.000658	0.0175	CbGeAlD
Gefitinib—CSNK1E—adipose tissue—type 2 diabetes mellitus	0.00065	0.0173	CbGeAlD
Gefitinib—MKNK2—cortex of kidney—type 2 diabetes mellitus	0.000645	0.0171	CbGeAlD
Gefitinib—IRAK1—cortex of kidney—type 2 diabetes mellitus	0.000645	0.0171	CbGeAlD
Gefitinib—IRAK4—adipose tissue—type 2 diabetes mellitus	0.00064	0.017	CbGeAlD
Gefitinib—MKNK1—cortex of kidney—type 2 diabetes mellitus	0.000637	0.0169	CbGeAlD
Gefitinib—ERBB3—adipose tissue—type 2 diabetes mellitus	0.000628	0.0167	CbGeAlD
Gefitinib—MKNK2—adipose tissue—type 2 diabetes mellitus	0.000597	0.0159	CbGeAlD
Gefitinib—IRAK1—adipose tissue—type 2 diabetes mellitus	0.000597	0.0159	CbGeAlD
Gefitinib—MKNK1—adipose tissue—type 2 diabetes mellitus	0.000589	0.0157	CbGeAlD
Gefitinib—STK10—cardiovascular system—type 2 diabetes mellitus	0.00055	0.0146	CbGeAlD
Gefitinib—STK10—kidney—type 2 diabetes mellitus	0.000538	0.0143	CbGeAlD
Gefitinib—Lapatinib—EGFR—type 2 diabetes mellitus	0.000534	0.124	CrCbGaD
Gefitinib—MAP2K5—cardiovascular system—type 2 diabetes mellitus	0.000491	0.0131	CbGeAlD
Gefitinib—STK10—adipose tissue—type 2 diabetes mellitus	0.000485	0.0129	CbGeAlD
Gefitinib—EGFR—liver—type 2 diabetes mellitus	0.000474	0.0126	CbGeAlD
Gefitinib—MAP2K5—cortex of kidney—type 2 diabetes mellitus	0.000468	0.0124	CbGeAlD
Gefitinib—CSNK1E—liver—type 2 diabetes mellitus	0.000456	0.0121	CbGeAlD
Gefitinib—IRAK4—liver—type 2 diabetes mellitus	0.000449	0.0119	CbGeAlD
Gefitinib—ERBB3—liver—type 2 diabetes mellitus	0.00044	0.0117	CbGeAlD
Gefitinib—MAP2K5—adipose tissue—type 2 diabetes mellitus	0.000433	0.0115	CbGeAlD
Gefitinib—MKNK2—liver—type 2 diabetes mellitus	0.000419	0.0111	CbGeAlD
Gefitinib—IRAK1—liver—type 2 diabetes mellitus	0.000419	0.0111	CbGeAlD
Gefitinib—MKNK1—liver—type 2 diabetes mellitus	0.000413	0.011	CbGeAlD
Gefitinib—Afatinib—EGFR—type 2 diabetes mellitus	0.000379	0.0882	CrCbGaD
Gefitinib—STK10—liver—type 2 diabetes mellitus	0.00034	0.00904	CbGeAlD
Gefitinib—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000307	0.00815	CbGeAlD
Gefitinib—MAP2K5—liver—type 2 diabetes mellitus	0.000304	0.00808	CbGeAlD
Gefitinib—Erlotinib—EGFR—type 2 diabetes mellitus	0.000268	0.0623	CrCbGaD
Gefitinib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000266	0.00707	CbGeAlD
Gefitinib—Vandetanib—SRC—type 2 diabetes mellitus	0.000262	0.0611	CrCbGaD
Gefitinib—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000247	0.00657	CbGeAlD
Gefitinib—ORM1—liver—type 2 diabetes mellitus	0.000247	0.00656	CbGeAlD
Gefitinib—Bosutinib—SRC—type 2 diabetes mellitus	0.000245	0.0571	CrCbGaD
Gefitinib—Minaprine—HTR2C—type 2 diabetes mellitus	0.000233	0.0543	CrCbGaD
Gefitinib—CYP1A1—kidney—type 2 diabetes mellitus	0.000222	0.0059	CbGeAlD
Gefitinib—CYP2C9—cardiovascular system—type 2 diabetes mellitus	0.000218	0.0058	CbGeAlD
Gefitinib—CYP3A5—kidney—type 2 diabetes mellitus	0.000217	0.00577	CbGeAlD
Gefitinib—ALB—liver—type 2 diabetes mellitus	0.000216	0.00575	CbGeAlD
Gefitinib—CYP3A5—pancreas—type 2 diabetes mellitus	0.000216	0.00573	CbGeAlD
Gefitinib—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000211	0.00562	CbGeAlD
Gefitinib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000211	0.0056	CbGeAlD
Gefitinib—Vandetanib—VEGFA—type 2 diabetes mellitus	0.000209	0.0486	CrCbGaD
Gefitinib—CYP1A1—adipose tissue—type 2 diabetes mellitus	0.0002	0.00532	CbGeAlD
Gefitinib—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.000196	0.0052	CbGeAlD
Gefitinib—Lapatinib—CYP3A4—type 2 diabetes mellitus	0.000195	0.0454	CrCbGaD
Gefitinib—Iloperidone—ADRA2A—type 2 diabetes mellitus	0.000185	0.043	CrCbGaD
Gefitinib—Cisapride—HTR2C—type 2 diabetes mellitus	0.000184	0.0429	CrCbGaD
Gefitinib—Vandetanib—EGFR—type 2 diabetes mellitus	0.000176	0.041	CrCbGaD
Gefitinib—CYP2C19—liver—type 2 diabetes mellitus	0.000174	0.00463	CbGeAlD
Gefitinib—Iloperidone—HTR2C—type 2 diabetes mellitus	0.00017	0.0396	CrCbGaD
Gefitinib—Bosutinib—EGFR—type 2 diabetes mellitus	0.000165	0.0384	CrCbGaD
Gefitinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000163	0.00433	CbGeAlD
Gefitinib—CYP3A4—kidney—type 2 diabetes mellitus	0.000163	0.00433	CbGeAlD
Gefitinib—CYP2D6—kidney—type 2 diabetes mellitus	0.00016	0.00426	CbGeAlD
Gefitinib—ABCG2—liver—type 2 diabetes mellitus	0.000148	0.00393	CbGeAlD
Gefitinib—Erlotinib—CYP1A2—type 2 diabetes mellitus	0.000148	0.0344	CrCbGaD
Gefitinib—CYP1A1—liver—type 2 diabetes mellitus	0.00014	0.00373	CbGeAlD
Gefitinib—ABCB1—retina—type 2 diabetes mellitus	0.000139	0.0037	CbGeAlD
Gefitinib—Cisapride—CYP1A2—type 2 diabetes mellitus	0.000139	0.0324	CrCbGaD
Gefitinib—CYP3A5—liver—type 2 diabetes mellitus	0.000137	0.00365	CbGeAlD
Gefitinib—CYP2C9—liver—type 2 diabetes mellitus	0.000135	0.00359	CbGeAlD
Gefitinib—Iloperidone—CYP2E1—type 2 diabetes mellitus	0.000135	0.0314	CrCbGaD
Gefitinib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000131	0.00349	CbGeAlD
Gefitinib—Angioedema—Orlistat—type 2 diabetes mellitus	0.000129	0.00103	CcSEcCtD
Gefitinib—Iloperidone—CYP1A2—type 2 diabetes mellitus	0.000128	0.0299	CrCbGaD
Gefitinib—Angiopathy—Irbesartan—type 2 diabetes mellitus	0.000128	0.00102	CcSEcCtD
Gefitinib—Malaise—Orlistat—type 2 diabetes mellitus	0.000127	0.00102	CcSEcCtD
Gefitinib—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000127	0.00102	CcSEcCtD
Gefitinib—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Gefitinib—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Gefitinib—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Gefitinib—Infection—Gliclazide—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Gefitinib—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Gefitinib—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Gefitinib—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000126	0.00101	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Ramipril—type 2 diabetes mellitus	0.000125	0.00101	CcSEcCtD
Gefitinib—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000125	0.00101	CcSEcCtD
Gefitinib—Erythema multiforme—Losartan—type 2 diabetes mellitus	0.000125	0.001	CcSEcCtD
Gefitinib—Cough—Valsartan—type 2 diabetes mellitus	0.000124	0.000997	CcSEcCtD
Gefitinib—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000124	0.000997	CcSEcCtD
Gefitinib—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000124	0.000996	CcSEcCtD
Gefitinib—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	0.000124	0.000994	CcSEcCtD
Gefitinib—Stomatitis—Ramipril—type 2 diabetes mellitus	0.000123	0.000989	CcSEcCtD
Gefitinib—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000123	0.000986	CcSEcCtD
Gefitinib—Conjunctivitis—Ramipril—type 2 diabetes mellitus	0.000123	0.000986	CcSEcCtD
Gefitinib—Cough—Orlistat—type 2 diabetes mellitus	0.000123	0.000986	CcSEcCtD
Gefitinib—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000123	0.000984	CcSEcCtD
Gefitinib—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000123	0.000983	CcSEcCtD
Gefitinib—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000123	0.000983	CcSEcCtD
Gefitinib—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000123	0.000982	CcSEcCtD
Gefitinib—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000122	0.000981	CcSEcCtD
Gefitinib—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000122	0.000978	CcSEcCtD
Gefitinib—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000122	0.000978	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000122	0.000976	CcSEcCtD
Gefitinib—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000121	0.00097	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000121	0.000966	CcSEcCtD
Gefitinib—Angiopathy—Losartan—type 2 diabetes mellitus	0.00012	0.000963	CcSEcCtD
Gefitinib—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.00012	0.000963	CcSEcCtD
Gefitinib—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	0.00012	0.000959	CcSEcCtD
Gefitinib—Epistaxis—Ramipril—type 2 diabetes mellitus	0.000119	0.000957	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000119	0.000955	CcSEcCtD
Gefitinib—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000119	0.000952	CcSEcCtD
Gefitinib—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000118	0.000949	CcSEcCtD
Gefitinib—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000118	0.000949	CcSEcCtD
Gefitinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000118	0.00313	CbGeAlD
Gefitinib—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000117	0.00094	CcSEcCtD
Gefitinib—Malaise—Metformin—type 2 diabetes mellitus	0.000117	0.000939	CcSEcCtD
Gefitinib—Alopecia—Losartan—type 2 diabetes mellitus	0.000117	0.000938	CcSEcCtD
Gefitinib—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000117	0.000938	CcSEcCtD
Gefitinib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000117	0.000935	CcSEcCtD
Gefitinib—Vomiting—Glipizide—type 2 diabetes mellitus	0.000117	0.000934	CcSEcCtD
Gefitinib—Infection—Valsartan—type 2 diabetes mellitus	0.000116	0.000927	CcSEcCtD
Gefitinib—Rash—Glipizide—type 2 diabetes mellitus	0.000116	0.000926	CcSEcCtD
Gefitinib—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000115	0.000925	CcSEcCtD
Gefitinib—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000115	0.000925	CcSEcCtD
Gefitinib—ABCB1—kidney—type 2 diabetes mellitus	0.000115	0.00307	CbGeAlD
Gefitinib—ABCB1—pancreas—type 2 diabetes mellitus	0.000115	0.00305	CbGeAlD
Gefitinib—Shock—Valsartan—type 2 diabetes mellitus	0.000115	0.000918	CcSEcCtD
Gefitinib—Infection—Orlistat—type 2 diabetes mellitus	0.000114	0.000916	CcSEcCtD
Gefitinib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000114	0.000915	CcSEcCtD
Gefitinib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000114	0.000913	CcSEcCtD
Gefitinib—Hepatitis—Ramipril—type 2 diabetes mellitus	0.000114	0.000911	CcSEcCtD
Gefitinib—Anaemia—Irbesartan—type 2 diabetes mellitus	0.000113	0.000908	CcSEcCtD
Gefitinib—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000113	0.000906	CcSEcCtD
Gefitinib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000113	0.000905	CcSEcCtD
Gefitinib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000113	0.000904	CcSEcCtD
Gefitinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000112	0.00299	CbGeAlD
Gefitinib—Urticaria—Glyburide—type 2 diabetes mellitus	0.000112	0.000898	CcSEcCtD
Gefitinib—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000112	0.000898	CcSEcCtD
Gefitinib—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.000112	0.000897	CcSEcCtD
Gefitinib—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000112	0.000895	CcSEcCtD
Gefitinib—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000112	0.000894	CcSEcCtD
Gefitinib—Anorexia—Valsartan—type 2 diabetes mellitus	0.000111	0.000889	CcSEcCtD
Gefitinib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000111	0.000887	CcSEcCtD
Gefitinib—Malaise—Irbesartan—type 2 diabetes mellitus	0.000111	0.000886	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.00011	0.00088	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000109	0.000877	CcSEcCtD
Gefitinib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000109	0.000875	CcSEcCtD
Gefitinib—Nausea—Glipizide—type 2 diabetes mellitus	0.000109	0.000873	CcSEcCtD
Gefitinib—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000109	0.000872	CcSEcCtD
Gefitinib—Hypotension—Valsartan—type 2 diabetes mellitus	0.000109	0.000872	CcSEcCtD
Gefitinib—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000108	0.000869	CcSEcCtD
Gefitinib—Constipation—Gliclazide—type 2 diabetes mellitus	0.000108	0.000868	CcSEcCtD
Gefitinib—Pain—Gliclazide—type 2 diabetes mellitus	0.000108	0.000868	CcSEcCtD
Gefitinib—Rash—Glimepiride—type 2 diabetes mellitus	0.000108	0.000864	CcSEcCtD
Gefitinib—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000108	0.000864	CcSEcCtD
Gefitinib—Rash—Sitagliptin—type 2 diabetes mellitus	0.000108	0.000862	CcSEcCtD
Gefitinib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000107	0.000861	CcSEcCtD
Gefitinib—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000107	0.000861	CcSEcCtD
Gefitinib—Cough—Irbesartan—type 2 diabetes mellitus	0.000107	0.000857	CcSEcCtD
Gefitinib—Anaemia—Losartan—type 2 diabetes mellitus	0.000107	0.000854	CcSEcCtD
Gefitinib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000106	0.000846	CcSEcCtD
Gefitinib—Angioedema—Losartan—type 2 diabetes mellitus	0.000105	0.000845	CcSEcCtD
Gefitinib—Infection—Metformin—type 2 diabetes mellitus	0.000105	0.000844	CcSEcCtD
Gefitinib—Shock—Metformin—type 2 diabetes mellitus	0.000104	0.000836	CcSEcCtD
Gefitinib—Malaise—Losartan—type 2 diabetes mellitus	0.000104	0.000834	CcSEcCtD
Gefitinib—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000104	0.00276	CbGeAlD
Gefitinib—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.000104	0.000833	CcSEcCtD
Gefitinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000104	0.000833	CcSEcCtD
Gefitinib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.000104	0.000832	CcSEcCtD
Gefitinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000104	0.000832	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000104	0.00083	CcSEcCtD
Gefitinib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.000104	0.00083	CcSEcCtD
Gefitinib—CYP3A4—liver—type 2 diabetes mellitus	0.000103	0.00274	CbGeAlD
Gefitinib—Skin disorder—Metformin—type 2 diabetes mellitus	0.000103	0.000825	CcSEcCtD
Gefitinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000102	0.000821	CcSEcCtD
Gefitinib—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000102	0.000818	CcSEcCtD
Gefitinib—Nausea—Glimepiride—type 2 diabetes mellitus	0.000102	0.000814	CcSEcCtD
Gefitinib—Arrhythmia—Ramipril—type 2 diabetes mellitus	0.000102	0.000813	CcSEcCtD
Gefitinib—CYP2D6—liver—type 2 diabetes mellitus	0.000101	0.00269	CbGeAlD
Gefitinib—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000101	0.000812	CcSEcCtD
Gefitinib—Asthenia—Glyburide—type 2 diabetes mellitus	0.000101	0.000811	CcSEcCtD
Gefitinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000101	0.000811	CcSEcCtD
Gefitinib—Anorexia—Metformin—type 2 diabetes mellitus	0.000101	0.00081	CcSEcCtD
Gefitinib—Cough—Losartan—type 2 diabetes mellitus	0.000101	0.000807	CcSEcCtD
Gefitinib—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000101	0.000807	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.0001	0.000805	CcSEcCtD
Gefitinib—Alopecia—Ramipril—type 2 diabetes mellitus	0.0001	0.000805	CcSEcCtD
Gefitinib—Fatigue—Valsartan—type 2 diabetes mellitus	0.0001	0.000804	CcSEcCtD
Gefitinib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.0001	0.000803	CcSEcCtD
Gefitinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.0001	0.000803	CcSEcCtD
Gefitinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.0001	0.000801	CcSEcCtD
Gefitinib—Pruritus—Glyburide—type 2 diabetes mellitus	9.98e-05	0.0008	CcSEcCtD
Gefitinib—Constipation—Valsartan—type 2 diabetes mellitus	9.95e-05	0.000798	CcSEcCtD
Gefitinib—Infection—Irbesartan—type 2 diabetes mellitus	9.94e-05	0.000796	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	9.93e-05	0.000796	CcSEcCtD
Gefitinib—Fatigue—Orlistat—type 2 diabetes mellitus	9.92e-05	0.000795	CcSEcCtD
Gefitinib—Hypotension—Metformin—type 2 diabetes mellitus	9.91e-05	0.000794	CcSEcCtD
Gefitinib—Malnutrition—Ramipril—type 2 diabetes mellitus	9.89e-05	0.000793	CcSEcCtD
Gefitinib—Shock—Irbesartan—type 2 diabetes mellitus	9.84e-05	0.000789	CcSEcCtD
Gefitinib—Pain—Orlistat—type 2 diabetes mellitus	9.84e-05	0.000788	CcSEcCtD
Gefitinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	9.81e-05	0.000786	CcSEcCtD
Gefitinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	9.81e-05	0.000786	CcSEcCtD
Gefitinib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	9.79e-05	0.000785	CcSEcCtD
Gefitinib—Erlotinib—CYP3A4—type 2 diabetes mellitus	9.78e-05	0.0227	CrCbGaD
Gefitinib—Rash—Bromocriptine—type 2 diabetes mellitus	9.73e-05	0.00078	CcSEcCtD
Gefitinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	9.72e-05	0.000779	CcSEcCtD
Gefitinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	9.72e-05	0.000779	CcSEcCtD
Gefitinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	9.65e-05	0.000774	CcSEcCtD
Gefitinib—Dry mouth—Losartan—type 2 diabetes mellitus	9.6e-05	0.00077	CcSEcCtD
Gefitinib—Anorexia—Irbesartan—type 2 diabetes mellitus	9.54e-05	0.000764	CcSEcCtD
Gefitinib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	9.52e-05	0.000763	CcSEcCtD
Gefitinib—Dyspnoea—Metformin—type 2 diabetes mellitus	9.45e-05	0.000757	CcSEcCtD
Gefitinib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	9.41e-05	0.000754	CcSEcCtD
Gefitinib—Infection—Losartan—type 2 diabetes mellitus	9.35e-05	0.000749	CcSEcCtD
Gefitinib—Hypotension—Irbesartan—type 2 diabetes mellitus	9.35e-05	0.000749	CcSEcCtD
Gefitinib—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	9.33e-05	0.000748	CcSEcCtD
Gefitinib—Shock—Losartan—type 2 diabetes mellitus	9.26e-05	0.000742	CcSEcCtD
Gefitinib—Urticaria—Valsartan—type 2 diabetes mellitus	9.25e-05	0.000741	CcSEcCtD
Gefitinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	9.23e-05	0.00074	CcSEcCtD
Gefitinib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	9.22e-05	0.000739	CcSEcCtD
Gefitinib—Decreased appetite—Metformin—type 2 diabetes mellitus	9.21e-05	0.000738	CcSEcCtD
Gefitinib—Cisapride—CYP3A4—type 2 diabetes mellitus	9.21e-05	0.0214	CrCbGaD
Gefitinib—Abdominal pain—Valsartan—type 2 diabetes mellitus	9.2e-05	0.000737	CcSEcCtD
Gefitinib—Nausea—Bromocriptine—type 2 diabetes mellitus	9.17e-05	0.000735	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	9.15e-05	0.000733	CcSEcCtD
Gefitinib—Fatigue—Metformin—type 2 diabetes mellitus	9.14e-05	0.000732	CcSEcCtD
Gefitinib—Urticaria—Orlistat—type 2 diabetes mellitus	9.14e-05	0.000732	CcSEcCtD
Gefitinib—Abdominal pain—Orlistat—type 2 diabetes mellitus	9.09e-05	0.000729	CcSEcCtD
Gefitinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	9.09e-05	0.000729	CcSEcCtD
Gefitinib—Asthenia—Gliclazide—type 2 diabetes mellitus	9.09e-05	0.000728	CcSEcCtD
Gefitinib—Constipation—Metformin—type 2 diabetes mellitus	9.06e-05	0.000726	CcSEcCtD
Gefitinib—Angioedema—Ramipril—type 2 diabetes mellitus	9.04e-05	0.000724	CcSEcCtD
Gefitinib—Anorexia—Losartan—type 2 diabetes mellitus	8.97e-05	0.000719	CcSEcCtD
Gefitinib—Vomiting—Glyburide—type 2 diabetes mellitus	8.97e-05	0.000719	CcSEcCtD
Gefitinib—Pruritus—Gliclazide—type 2 diabetes mellitus	8.96e-05	0.000718	CcSEcCtD
Gefitinib—Malaise—Ramipril—type 2 diabetes mellitus	8.92e-05	0.000715	CcSEcCtD
Gefitinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	8.92e-05	0.000715	CcSEcCtD
Gefitinib—Rash—Glyburide—type 2 diabetes mellitus	8.9e-05	0.000713	CcSEcCtD
Gefitinib—Dermatitis—Glyburide—type 2 diabetes mellitus	8.89e-05	0.000712	CcSEcCtD
Gefitinib—Hypotension—Losartan—type 2 diabetes mellitus	8.8e-05	0.000705	CcSEcCtD
Gefitinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	8.7e-05	0.000697	CcSEcCtD
Gefitinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	8.67e-05	0.000695	CcSEcCtD
Gefitinib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	8.67e-05	0.000695	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	8.64e-05	0.000692	CcSEcCtD
Gefitinib—Cough—Ramipril—type 2 diabetes mellitus	8.63e-05	0.000692	CcSEcCtD
Gefitinib—Fatigue—Irbesartan—type 2 diabetes mellitus	8.62e-05	0.000691	CcSEcCtD
Gefitinib—Hypersensitivity—Valsartan—type 2 diabetes mellitus	8.58e-05	0.000687	CcSEcCtD
Gefitinib—Pain—Irbesartan—type 2 diabetes mellitus	8.55e-05	0.000686	CcSEcCtD
Gefitinib—Constipation—Irbesartan—type 2 diabetes mellitus	8.55e-05	0.000686	CcSEcCtD
Gefitinib—Erlotinib—ALB—type 2 diabetes mellitus	8.53e-05	0.0198	CrCbGaD
Gefitinib—Iloperidone—CYP3A4—type 2 diabetes mellitus	8.5e-05	0.0198	CrCbGaD
Gefitinib—Hypersensitivity—Orlistat—type 2 diabetes mellitus	8.47e-05	0.000679	CcSEcCtD
Gefitinib—Urticaria—Metformin—type 2 diabetes mellitus	8.42e-05	0.000675	CcSEcCtD
Gefitinib—Dyspnoea—Losartan—type 2 diabetes mellitus	8.39e-05	0.000673	CcSEcCtD
Gefitinib—Nausea—Glyburide—type 2 diabetes mellitus	8.38e-05	0.000672	CcSEcCtD
Gefitinib—Abdominal pain—Metformin—type 2 diabetes mellitus	8.38e-05	0.000672	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	8.36e-05	0.00067	CcSEcCtD
Gefitinib—Asthenia—Valsartan—type 2 diabetes mellitus	8.35e-05	0.000669	CcSEcCtD
Gefitinib—Asthenia—Orlistat—type 2 diabetes mellitus	8.25e-05	0.000661	CcSEcCtD
Gefitinib—Pruritus—Valsartan—type 2 diabetes mellitus	8.24e-05	0.00066	CcSEcCtD
Gefitinib—Dry mouth—Ramipril—type 2 diabetes mellitus	8.24e-05	0.00066	CcSEcCtD
Gefitinib—Decreased appetite—Losartan—type 2 diabetes mellitus	8.18e-05	0.000656	CcSEcCtD
Gefitinib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	8.18e-05	0.000656	CcSEcCtD
Gefitinib—Pruritus—Orlistat—type 2 diabetes mellitus	8.14e-05	0.000652	CcSEcCtD
Gefitinib—Fatigue—Losartan—type 2 diabetes mellitus	8.12e-05	0.00065	CcSEcCtD
Gefitinib—Vomiting—Gliclazide—type 2 diabetes mellitus	8.06e-05	0.000646	CcSEcCtD
Gefitinib—Pain—Losartan—type 2 diabetes mellitus	8.05e-05	0.000645	CcSEcCtD
Gefitinib—Constipation—Losartan—type 2 diabetes mellitus	8.05e-05	0.000645	CcSEcCtD
Gefitinib—Rash—Gliclazide—type 2 diabetes mellitus	7.99e-05	0.00064	CcSEcCtD
Gefitinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	7.98e-05	0.00064	CcSEcCtD
Gefitinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	7.96e-05	0.000638	CcSEcCtD
Gefitinib—Urticaria—Irbesartan—type 2 diabetes mellitus	7.95e-05	0.000637	CcSEcCtD
Gefitinib—Shock—Ramipril—type 2 diabetes mellitus	7.94e-05	0.000636	CcSEcCtD
Gefitinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	7.92e-05	0.000634	CcSEcCtD
Gefitinib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	7.91e-05	0.000634	CcSEcCtD
Gefitinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	7.91e-05	0.000634	CcSEcCtD
Gefitinib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	7.9e-05	0.000633	CcSEcCtD
Gefitinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	7.87e-05	0.000631	CcSEcCtD
Gefitinib—Skin disorder—Ramipril—type 2 diabetes mellitus	7.84e-05	0.000628	CcSEcCtD
Gefitinib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	7.7e-05	0.000617	CcSEcCtD
Gefitinib—Anorexia—Ramipril—type 2 diabetes mellitus	7.69e-05	0.000617	CcSEcCtD
Gefitinib—Asthenia—Metformin—type 2 diabetes mellitus	7.61e-05	0.000609	CcSEcCtD
Gefitinib—Hypotension—Ramipril—type 2 diabetes mellitus	7.54e-05	0.000604	CcSEcCtD
Gefitinib—Nausea—Gliclazide—type 2 diabetes mellitus	7.53e-05	0.000603	CcSEcCtD
Gefitinib—Pruritus—Metformin—type 2 diabetes mellitus	7.5e-05	0.000601	CcSEcCtD
Gefitinib—Urticaria—Losartan—type 2 diabetes mellitus	7.48e-05	0.000599	CcSEcCtD
Gefitinib—Abdominal pain—Losartan—type 2 diabetes mellitus	7.44e-05	0.000596	CcSEcCtD
Gefitinib—Body temperature increased—Losartan—type 2 diabetes mellitus	7.44e-05	0.000596	CcSEcCtD
Gefitinib—Vomiting—Valsartan—type 2 diabetes mellitus	7.4e-05	0.000593	CcSEcCtD
Gefitinib—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	7.37e-05	0.000591	CcSEcCtD
Gefitinib—Rash—Valsartan—type 2 diabetes mellitus	7.34e-05	0.000588	CcSEcCtD
Gefitinib—Dermatitis—Valsartan—type 2 diabetes mellitus	7.33e-05	0.000588	CcSEcCtD
Gefitinib—Vomiting—Orlistat—type 2 diabetes mellitus	7.31e-05	0.000586	CcSEcCtD
Gefitinib—ABCB1—liver—type 2 diabetes mellitus	7.29e-05	0.00194	CbGeAlD
Gefitinib—Diarrhoea—Metformin—type 2 diabetes mellitus	7.25e-05	0.000581	CcSEcCtD
Gefitinib—Rash—Orlistat—type 2 diabetes mellitus	7.25e-05	0.000581	CcSEcCtD
Gefitinib—Dermatitis—Orlistat—type 2 diabetes mellitus	7.25e-05	0.000581	CcSEcCtD
Gefitinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	7.2e-05	0.000577	CcSEcCtD
Gefitinib—Asthenia—Irbesartan—type 2 diabetes mellitus	7.18e-05	0.000575	CcSEcCtD
Gefitinib—Pruritus—Irbesartan—type 2 diabetes mellitus	7.08e-05	0.000567	CcSEcCtD
Gefitinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	7.02e-05	0.000562	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	6.97e-05	0.000558	CcSEcCtD
Gefitinib—Fatigue—Ramipril—type 2 diabetes mellitus	6.96e-05	0.000558	CcSEcCtD
Gefitinib—Hypersensitivity—Losartan—type 2 diabetes mellitus	6.94e-05	0.000556	CcSEcCtD
Gefitinib—Nausea—Valsartan—type 2 diabetes mellitus	6.91e-05	0.000554	CcSEcCtD
Gefitinib—Constipation—Ramipril—type 2 diabetes mellitus	6.9e-05	0.000553	CcSEcCtD
Gefitinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	6.84e-05	0.000548	CcSEcCtD
Gefitinib—Nausea—Orlistat—type 2 diabetes mellitus	6.83e-05	0.000547	CcSEcCtD
Gefitinib—Asthenia—Losartan—type 2 diabetes mellitus	6.75e-05	0.000541	CcSEcCtD
Gefitinib—Vomiting—Metformin—type 2 diabetes mellitus	6.74e-05	0.00054	CcSEcCtD
Gefitinib—Rash—Metformin—type 2 diabetes mellitus	6.68e-05	0.000536	CcSEcCtD
Gefitinib—Dermatitis—Metformin—type 2 diabetes mellitus	6.68e-05	0.000535	CcSEcCtD
Gefitinib—Pruritus—Losartan—type 2 diabetes mellitus	6.66e-05	0.000534	CcSEcCtD
Gefitinib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	6.6e-05	0.000529	CcSEcCtD
Gefitinib—Diarrhoea—Losartan—type 2 diabetes mellitus	6.44e-05	0.000516	CcSEcCtD
Gefitinib—Vandetanib—CYP3A4—type 2 diabetes mellitus	6.44e-05	0.015	CrCbGaD
Gefitinib—Urticaria—Ramipril—type 2 diabetes mellitus	6.41e-05	0.000514	CcSEcCtD
Gefitinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	6.38e-05	0.000511	CcSEcCtD
Gefitinib—Abdominal pain—Ramipril—type 2 diabetes mellitus	6.38e-05	0.000511	CcSEcCtD
Gefitinib—Vomiting—Irbesartan—type 2 diabetes mellitus	6.36e-05	0.00051	CcSEcCtD
Gefitinib—Rash—Irbesartan—type 2 diabetes mellitus	6.31e-05	0.000505	CcSEcCtD
Gefitinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	6.3e-05	0.000505	CcSEcCtD
Gefitinib—Nausea—Metformin—type 2 diabetes mellitus	6.3e-05	0.000505	CcSEcCtD
Gefitinib—Bosutinib—CYP3A4—type 2 diabetes mellitus	6.02e-05	0.014	CrCbGaD
Gefitinib—Vomiting—Losartan—type 2 diabetes mellitus	5.99e-05	0.00048	CcSEcCtD
Gefitinib—Hypersensitivity—Ramipril—type 2 diabetes mellitus	5.95e-05	0.000477	CcSEcCtD
Gefitinib—Nausea—Irbesartan—type 2 diabetes mellitus	5.94e-05	0.000476	CcSEcCtD
Gefitinib—Rash—Losartan—type 2 diabetes mellitus	5.94e-05	0.000476	CcSEcCtD
Gefitinib—Dermatitis—Losartan—type 2 diabetes mellitus	5.93e-05	0.000475	CcSEcCtD
Gefitinib—Asthenia—Ramipril—type 2 diabetes mellitus	5.79e-05	0.000464	CcSEcCtD
Gefitinib—Pruritus—Ramipril—type 2 diabetes mellitus	5.71e-05	0.000458	CcSEcCtD
Gefitinib—Vandetanib—ALB—type 2 diabetes mellitus	5.62e-05	0.0131	CrCbGaD
Gefitinib—Nausea—Losartan—type 2 diabetes mellitus	5.59e-05	0.000448	CcSEcCtD
Gefitinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	5.52e-05	0.000443	CcSEcCtD
Gefitinib—Vomiting—Ramipril—type 2 diabetes mellitus	5.13e-05	0.000411	CcSEcCtD
Gefitinib—Rash—Ramipril—type 2 diabetes mellitus	5.09e-05	0.000408	CcSEcCtD
Gefitinib—Dermatitis—Ramipril—type 2 diabetes mellitus	5.09e-05	0.000407	CcSEcCtD
Gefitinib—Nausea—Ramipril—type 2 diabetes mellitus	4.79e-05	0.000384	CcSEcCtD
Gefitinib—IRAK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.01e-06	1.9e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CAT—type 2 diabetes mellitus	2.01e-06	1.89e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—AKT1—type 2 diabetes mellitus	2e-06	1.88e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ADCY5—type 2 diabetes mellitus	2e-06	1.88e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL6—type 2 diabetes mellitus	1.99e-06	1.88e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	1.99e-06	1.88e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GPX1—type 2 diabetes mellitus	1.99e-06	1.88e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—AKT1—type 2 diabetes mellitus	1.99e-06	1.87e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	1.99e-06	1.87e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ALB—type 2 diabetes mellitus	1.98e-06	1.87e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.98e-06	1.86e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP3A4—type 2 diabetes mellitus	1.97e-06	1.86e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	1.96e-06	1.85e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	1.96e-06	1.85e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	1.96e-06	1.85e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL6—type 2 diabetes mellitus	1.96e-06	1.84e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOB—type 2 diabetes mellitus	1.95e-06	1.84e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	1.95e-06	1.83e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—SLC2A4—type 2 diabetes mellitus	1.94e-06	1.83e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GCG—type 2 diabetes mellitus	1.94e-06	1.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SRC—type 2 diabetes mellitus	1.94e-06	1.83e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CD36—type 2 diabetes mellitus	1.94e-06	1.83e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—INS—type 2 diabetes mellitus	1.93e-06	1.82e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.92e-06	1.8e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	1.91e-06	1.8e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	1.91e-06	1.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.9e-06	1.79e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	1.9e-06	1.79e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	1.89e-06	1.78e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	1.89e-06	1.78e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.88e-06	1.77e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.87e-06	1.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.87e-06	1.76e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—LPL—type 2 diabetes mellitus	1.86e-06	1.75e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	1.85e-06	1.74e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	1.85e-06	1.74e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.84e-06	1.73e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—MTHFR—type 2 diabetes mellitus	1.84e-06	1.73e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.84e-06	1.73e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GNB3—type 2 diabetes mellitus	1.84e-06	1.73e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.83e-06	1.72e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HMOX1—type 2 diabetes mellitus	1.83e-06	1.72e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	1.82e-06	1.72e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	1.82e-06	1.71e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GPX1—type 2 diabetes mellitus	1.82e-06	1.71e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	1.81e-06	1.71e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—AKT1—type 2 diabetes mellitus	1.8e-06	1.7e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARA—type 2 diabetes mellitus	1.8e-06	1.7e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CAT—type 2 diabetes mellitus	1.8e-06	1.7e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—type 2 diabetes mellitus	1.79e-06	1.69e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.79e-06	1.69e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	1.79e-06	1.69e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	1.79e-06	1.69e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	1.78e-06	1.68e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.78e-06	1.67e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CD36—type 2 diabetes mellitus	1.77e-06	1.67e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	1.76e-06	1.66e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOB—type 2 diabetes mellitus	1.75e-06	1.65e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AGT—type 2 diabetes mellitus	1.75e-06	1.65e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	1.75e-06	1.65e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	1.73e-06	1.63e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	1.72e-06	1.62e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CALM1—type 2 diabetes mellitus	1.72e-06	1.62e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOE—type 2 diabetes mellitus	1.71e-06	1.61e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	1.71e-06	1.61e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTM1—type 2 diabetes mellitus	1.7e-06	1.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.7e-06	1.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.7e-06	1.6e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—APOA1—type 2 diabetes mellitus	1.69e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	1.69e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	1.69e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	1.69e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.69e-06	1.59e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	1.68e-06	1.58e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.68e-06	1.58e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	1.68e-06	1.58e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.67e-06	1.58e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GNB3—type 2 diabetes mellitus	1.67e-06	1.58e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—LPL—type 2 diabetes mellitus	1.67e-06	1.57e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HMOX1—type 2 diabetes mellitus	1.67e-06	1.57e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	1.66e-06	1.57e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	1.66e-06	1.56e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	1.66e-06	1.56e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	1.65e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	1.65e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	1.65e-06	1.55e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.64e-06	1.55e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARA—type 2 diabetes mellitus	1.64e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CAT—type 2 diabetes mellitus	1.64e-06	1.55e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	1.64e-06	1.54e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ADCY5—type 2 diabetes mellitus	1.64e-06	1.54e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	1.63e-06	1.54e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GPX1—type 2 diabetes mellitus	1.63e-06	1.54e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	1.61e-06	1.52e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	1.61e-06	1.51e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFB1—type 2 diabetes mellitus	1.6e-06	1.51e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RELA—type 2 diabetes mellitus	1.6e-06	1.5e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	1.6e-06	1.5e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOB—type 2 diabetes mellitus	1.6e-06	1.5e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AGT—type 2 diabetes mellitus	1.59e-06	1.5e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	1.59e-06	1.5e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	1.59e-06	1.5e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CD36—type 2 diabetes mellitus	1.59e-06	1.5e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	1.58e-06	1.49e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL6—type 2 diabetes mellitus	1.58e-06	1.48e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPP2CA—type 2 diabetes mellitus	1.57e-06	1.48e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CALM1—type 2 diabetes mellitus	1.57e-06	1.48e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	1.57e-06	1.48e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOE—type 2 diabetes mellitus	1.56e-06	1.47e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTM1—type 2 diabetes mellitus	1.55e-06	1.46e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	1.55e-06	1.46e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	1.55e-06	1.46e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—APOA1—type 2 diabetes mellitus	1.54e-06	1.45e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	1.54e-06	1.45e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	1.53e-06	1.44e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—LPL—type 2 diabetes mellitus	1.52e-06	1.44e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.52e-06	1.43e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	1.5e-06	1.42e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—MTHFR—type 2 diabetes mellitus	1.5e-06	1.42e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	1.5e-06	1.41e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ADCY5—type 2 diabetes mellitus	1.49e-06	1.41e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PPARG—type 2 diabetes mellitus	1.49e-06	1.4e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GPX1—type 2 diabetes mellitus	1.49e-06	1.4e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	1.48e-06	1.39e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	1.48e-06	1.39e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	1.48e-06	1.39e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARA—type 2 diabetes mellitus	1.48e-06	1.39e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	1.47e-06	1.38e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—INS—type 2 diabetes mellitus	1.46e-06	1.38e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	1.46e-06	1.38e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.45e-06	1.37e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	1.45e-06	1.37e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CD36—type 2 diabetes mellitus	1.45e-06	1.36e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	1.44e-06	1.36e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	1.44e-06	1.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.44e-06	1.36e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	1.44e-06	1.35e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL6—type 2 diabetes mellitus	1.43e-06	1.35e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPP2CA—type 2 diabetes mellitus	1.43e-06	1.35e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AGT—type 2 diabetes mellitus	1.43e-06	1.35e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	1.42e-06	1.34e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	1.41e-06	1.32e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CALM1—type 2 diabetes mellitus	1.41e-06	1.32e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.4e-06	1.32e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOE—type 2 diabetes mellitus	1.4e-06	1.32e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	1.4e-06	1.31e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—APOA1—type 2 diabetes mellitus	1.38e-06	1.3e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.38e-06	1.3e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	1.37e-06	1.29e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—MTHFR—type 2 diabetes mellitus	1.37e-06	1.29e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	1.37e-06	1.29e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.36e-06	1.28e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PPARG—type 2 diabetes mellitus	1.36e-06	1.28e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.36e-06	1.28e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	1.36e-06	1.28e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	1.36e-06	1.28e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	1.35e-06	1.27e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	1.35e-06	1.27e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.35e-06	1.27e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARA—type 2 diabetes mellitus	1.35e-06	1.27e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ALB—type 2 diabetes mellitus	1.34e-06	1.26e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	1.34e-06	1.26e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	1.34e-06	1.26e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—INS—type 2 diabetes mellitus	1.33e-06	1.26e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	1.33e-06	1.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.32e-06	1.24e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.31e-06	1.24e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL6—type 2 diabetes mellitus	1.31e-06	1.23e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AGT—type 2 diabetes mellitus	1.3e-06	1.23e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.29e-06	1.22e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.29e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.28e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NOS3—type 2 diabetes mellitus	1.28e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CALM1—type 2 diabetes mellitus	1.28e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	1.28e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	1.28e-06	1.21e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOE—type 2 diabetes mellitus	1.28e-06	1.2e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.27e-06	1.2e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.26e-06	1.19e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—APOA1—type 2 diabetes mellitus	1.26e-06	1.19e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—type 2 diabetes mellitus	1.25e-06	1.18e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	1.24e-06	1.17e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.22e-06	1.15e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PPARG—type 2 diabetes mellitus	1.22e-06	1.15e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—IL6—type 2 diabetes mellitus	1.21e-06	1.14e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—AKT1—type 2 diabetes mellitus	1.21e-06	1.14e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—INS—type 2 diabetes mellitus	1.2e-06	1.13e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.19e-06	1.12e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—type 2 diabetes mellitus	1.17e-06	1.1e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NOS3—type 2 diabetes mellitus	1.17e-06	1.1e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	1.17e-06	1.1e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.17e-06	1.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.17e-06	1.1e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.12e-06	1.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.12e-06	1.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—AKT1—type 2 diabetes mellitus	1.11e-06	1.05e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PPARG—type 2 diabetes mellitus	1.11e-06	1.05e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.1e-06	1.04e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.1e-06	1.04e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.1e-06	1.04e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.1e-06	1.04e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ALB—type 2 diabetes mellitus	1.1e-06	1.03e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—INS—type 2 diabetes mellitus	1.09e-06	1.03e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.08e-06	1.02e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.07e-06	1.01e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	1.07e-06	1.01e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.05e-06	9.91e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PIK3R1—type 2 diabetes mellitus	1.05e-06	9.89e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NOS3—type 2 diabetes mellitus	1.05e-06	9.89e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.02e-06	9.65e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.02e-06	9.65e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.02e-06	9.64e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.01e-06	9.51e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1e-06	9.47e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ALB—type 2 diabetes mellitus	1e-06	9.42e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	9.84e-07	9.27e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	9.8e-07	9.24e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	9.65e-07	9.09e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	9.65e-07	9.09e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—type 2 diabetes mellitus	9.6e-07	9.04e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PIK3R1—type 2 diabetes mellitus	9.57e-07	9.01e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NOS3—type 2 diabetes mellitus	9.57e-07	9.01e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	9.55e-07	8.99e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	9.43e-07	8.88e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	9.37e-07	8.82e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	9.05e-07	8.52e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	8.87e-07	8.36e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	8.83e-07	8.32e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—type 2 diabetes mellitus	8.75e-07	8.24e-06	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	8.71e-07	8.2e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	8.6e-07	8.1e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL6—type 2 diabetes mellitus	8.45e-07	7.96e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	8.45e-07	7.96e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	8.42e-07	7.93e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	8.33e-07	7.84e-06	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—AKT1—type 2 diabetes mellitus	7.8e-07	7.35e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	7.34e-07	6.91e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	7.19e-07	6.78e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	6.6e-07	6.21e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	6.31e-07	5.94e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	6.31e-07	5.94e-06	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	6.24e-07	5.88e-06	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—AKT1—type 2 diabetes mellitus	5.89e-07	5.55e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	5.77e-07	5.44e-06	CbGpPWpGaD
Gefitinib—ALB—Metabolism—AKT1—type 2 diabetes mellitus	5.37e-07	5.06e-06	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—AKT1—type 2 diabetes mellitus	4.82e-07	4.54e-06	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	4.71e-07	4.44e-06	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	4.44e-07	4.18e-06	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—AKT1—type 2 diabetes mellitus	4.4e-07	4.14e-06	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	2.9e-07	2.73e-06	CbGpPWpGaD
